Abstract
Despite the availability of novel treatment options for patients with advanced melanoma, adjuvant treatment selection and hence prognosis for these patients continues to be suboptimal. Sentinel lymph node biopsy (SLNB), the standard practice to classify patients’ melanoma stage and guide adjuvant treatment decisions, can fail to accurately identify a significant proportion of patients that require adjuvant treatment with immunotherapy. A new biomarker, LY75, could be used in the diagnostic pathway to improve adjuvant treatment decisions, patient outcomes and cost-effectiveness. The aim of this study was to perform an early health technology assessment to evaluate the potential added value of LY75 in terms of costs and quality-adjusted life-years (QALY).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
